Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma

NCT06919939 is registered in ClinicalTrials.gov with University of Miami as lead sponsor.

NCT NCT06919939
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06919939 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma
Lead sponsor
University of Miami
Phase
Phase 2
Overall status
Recruiting
Start date
January 7, 2026
Completion date
January 7, 2031
Enrollment
26 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

large b-cell lymphoma, relapse